Chiron, Genentech, Genetics Institute sales and marketing update

The PTO decision won't affect the Factor VIII landscape because of a royalty-free 1988 cross-licensing agreement between Miles (now Bayer) and Baxter Healthcare Corp., the Factor VIII licensees of GNE and GENIZ, respectively. The patent will be included in that cross-license. Factor VIII is used to treat hemophilia. ...